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Abstract 
Objective: The incidence of thyroid cancer, the most common endocrine malignancy, has 
increased dramatically in the last fifty years. This article will review the standard approach to 
thyroid cancer treatment as well as novel therapies under investigation. We will also address 
potential cost considerations in the management of thyroid cancer. 
Study Design: A comprehensive literature search was performed. 
Methods: Review article. 
Results: The high prevalence of thyroid cancer and the availability of novel therapies for pa-
tients  with  metastatic  disease  have  potential  economic  implications  that  have  not  been 
well-studied. Because many patients likely have very low morbidity from their cancers, better 
tools to identify the lowest risk patients are needed in order to prevent overtreatment. 
Improved risk stratification should include recognizing patients who are unlikely to benefit 
from radioactive iodine therapy after initial surgery and identifying those with indolent and 
asymptomatic metastatic disease that are unlikely to benefit from novel therapies. In patients 
with advanced incurable disease, randomized-controlled studies to assess the efficacy of novel 
agents are needed to determine if the costs associated with new agents are warranted.  
Conclusions: Health care costs associated with the increased diagnosis of thyroid cancer 
remain unknown but are worthy of further research. 
Key  words:  differentiated  thyroid  cancer,  radioactive  iodine,  targeted  therapy,  clinical  trials, 
pharmacoeconomics 
Background/Epidemiology of Thyroid Can-
cer in the United States 
Thyroid cancer is the most common endocrine 
malignancy, with an estimated 44,670 new cases di-
agnosed in the United States in 2010. Its prevalence 
continues to rise; in 2008 it became the sixth most di-
agnosed cancer in women.1 For reasons that are un-
clear, thyroid cancer is 2-3 fold more common in fe-
males  than  males.  Although  the  peak  incidence  of 
thyroid cancer diagnosis is 45 to 49 years in women 
and 65 to 69 years in men, it does affect young people. 
Thyroid  cancer  accounts  for  approximately  10%  of 
malignancies  diagnosed  in  persons  aged  15  to  29 
years.2 
 Thyroid carcinoma can arise from either follicu-
lar  or  non-follicular  thyroid  cells.  Follicular  cancers 
include papillary thyroid cancer (PTC, 80%), follicular 
thyroid cancer (FTC, up to 11%), Hürthle cell cancer 
(HCC, 3%) and anaplastic thyroid cancer (ATC, 2%). 
PTC  and  FTC,  which  together  account  for  the  vast 
majority of cancers, are commonly referred to togeth-
er  as  differentiated  thyroid  cancer  (DTC).  HCC,  a 
subtype of FTC, is often classified on its own because 
it has a distinct histological appearance and is often 
less responsive to standard therapy. Similar to HCC, Journal of Cancer 2011, 2 
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several subtypes of DTC, including tall cell, columnar 
and insular thyroid cancers, are thought to be more 
aggressive. In contrast to DTC, ATC represents un-
differentiated  thyroid  cancer.  Medullary  thyroid 
cancer (MTC) arises from non-follicular thyroid cells 
called  calcitonin-producing  cells  and  accounts  for 
about 4% of thyroid cancers.  
 PTC accounts for the increase in new diagnoses 
of thyroid carcinoma. The reason for the increase in 
incident and prevalent cases is  not clear, but many 
believe it is due to the widespread use of radiology 
tests done for other reasons that detect small nonpal-
pable thyroid cancers. Consistent with this theory is 
that the death rate from thyroid cancer has remained 
stable despite the increase in cases. However, a recent 
analysis suggests that all stages of thyroid cancer are 
increasing,  a  finding  that  cannot  be  explained  by 
surveillance alone.3 Because PTC accounts for the in-
crease in thyroid cancer burden, this review will focus 
on  its  management.  Since  PTC  and  FTC  are  often 
treated with similar therapy, we will collectively refer 
to this group of cancers as DTC.  
 DTC is considered the least aggressive type of 
thyroid  cancer  and  has,  in  general,  an  excellent 
prognosis. Overall, greater than 90% of patients with 
thyroid cancer are alive at 10 years after diagnosis. 
This reassuring number is attributed to the fact that 
most people with thyroid  cancer have low-risk dis-
ease.  However,  a  small  percentage  of  patients  with 
DTC  exhibit  more  aggressive  disease.  Of  the  ap-
proximately 1,690 people who die yearly from thyroid 
cancer in the United States, about 70% percent carry 
the  diagnosis  of  DTC.1,  4  The  prognosis  of  patients 
with metastatic DTC is difficult to predict. Some pa-
tients  with  metastatic  DTC  have  stable  or 
slow-growing disease and maintain good quality of 
life without therapy. Others, however, develop pro-
gressive  disease  that  is  not  amenable  to  traditional 
therapy and, as a result, suffer increased morbidity 
and mortality from their cancer. Five-year survival is 
lower in patients with distant disease (56%) compared 
with  local  (99.7%)  or  regional  (96.9%)  disease.1  Alt-
hough it is difficult to predict who will go on to de-
velop  progressive  disease,  certain  factors  are  impli-
cated in increasing an individual’s particular risk for 
developing  progressive  cancer.  For  example,  age 
greater than 45 years of age, male gender, radioactive 
iodine  resistance,  and  positive  FDG  uptake  on  PET 
scanning have been associated with poorer prognosis 
in DTC.  
Current Treatment Options in Thyroid Can-
cer 
 Initial treatment for DTC includes surgery, ra-
dioactive  iodine  treatment  and  thyroid  hormone 
suppression therapy. Standard of care recommenda-
tions are based largely on retrospective data. A pro-
spective randomized trial to determine optimal ther-
apy would be prohibitively long and expensive be-
cause  survival  rates  are  excellent.  The  lack  of  pro-
spective data may lead to overtreatment of patients 
with low-risk disease who may have had no morbid-
ity or  mortality from their cancers if left untreated. 
Clinically unrecognized thyroid cancer has been seen 
in 4  - 35.6% of autopsies, which  is far greater than 
prevalence of diagnosed cancer.5-8 Still, because up to 
35% of patients, including those with low-risk tumors, 
have recurrences,9 most clinicians recommend thera-
py.  
 Total thyroidectomy is the preferred surgery for 
DTC. Lobectomy is only considered appropriate for 
small, isolated tumors (less than 1 cm) without evi-
dence of local spread. In retrospective studies, total 
thyroidectomy  has  been  shown  to  improve  dis-
ease-free  survival  and  reduce  recurrence  rates.10-12 
Total thyroidectomy allows for adequate staging and, 
when clinically appropriate, subsequent therapy with 
radioactive iodine (RAI, 131I). In addition, as many as 
30-85%  of  patients  have  multifocal  disease;13  this  is 
not always appreciated until surgical specimens are 
evaluated.  
 A  small  amount  of  thyroid  tissue,  called  the 
thyroid remnant, is often left after total thyroidecto-
my. RAI can be administered postoperatively to de-
stroy any remaining thyroid cells, normal or malig-
nant. RAI improves the specificity of future surveil-
lance imaging to detect recurrent disease. It also al-
lows  clinicians  to  monitor  serum  thyroglobulin,  a 
protein made by thyroid follicular cells, as a marker of 
disease. Because thyroid stimulating hormone (TSH) 
stimulation increases iodine uptake in thyroid cells, 
patients are withdrawn from thyroid hormone ther-
apy or treated with recombinant human TSH (rhTSH) 
in order to drive 131I into remaining cells. Most com-
monly, therapy with 131I is given as fixed doses, with 
small cancers confined to the thyroid receiving low 
doses (30 mCi) and more advanced cancers receiving 
higher doses (usually up to 200 mCi when lung me-
tastases are present).  
 Data suggest that high-risk patients (Stage III or 
IV) gain from RAI in terms of decreased disease pro-
gression and mortality.13-15 In contrast, the benefits of 
RAI in low-risk patients are uncertain and should be 
used selectively. Data suggest that RAI decreases re-
currence rates in low-risk patients with tumors great-
er than 1.5 cm, but whether it improves cause-specific 
survival is unclear.12, 14-16 RAI treatment has not been 
shown  to  decrease  recurrence  rates  or  death  in  pa-Journal of Cancer 2011, 2 
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tients with isolated tumors less than 1.5 cm.12, 17, 18 Hay 
et al., reviewed PTC cases managed at the Mayo Clinic 
between 1940 – 1999.18 Despite the increased use of 
RAI during this period, no significant improvement in 
cause-specific  mortality  or  tumor  recurrence  were 
observed in low-risk patients. These findings suggest 
that  RAI  should  not  be  given  routinely  to  low-risk 
patients.  Other  researchers  have  suggested  basing 
RAI decision-making in low-risk patients on whether 
a stimulated Tg is detectable three months postopera-
tively.19  Vaisman  et  al.  found  that  of  104  patients, 
56.7% had an undetectable stimulated Tg; only 1 of 
these  patients  received  RAI.  If  widely  applied,  less 
RAI administration may decrease health care spend-
ing. In addition to cost, RAI does have potential side 
effects,  including  damage  to  salivary  glands,  bone 
marrow, and gonads, especially when given in high 
and  cumulative  doses.  Therefore,  its  use  should  be 
targeted at patients who are likely benefit from ther-
apy.  
 The third part to standard DTC therapy is thy-
roid  hormone  suppression  therapy.  Because  TSH 
stimulates  thyroid  growth,  the  goal  of  suppression 
therapy is to keep TSH levels low. The degree of TSH 
suppression depends on the risk of the cancer, with 
only high-risk cancers requiring aggressive lowering 
of TSH. Several series have shown decreased recur-
rence rates and cancer-related mortality with thyroid 
hormone suppression therapy in high-risk patients.20 
There  is  no  evidence  that  low  risk  patients  require 
suppression.13 In fact, the increased risk of atrial fi-
brillation and bone loss from TSH suppression make 
aggressive TSH-lowering undesirable in low-risk pa-
tients.  
  Because recurrences have been reported some-
times  decades  from  initial  treatment,9  patients  with 
thyroid  cancer  require  lifelong  monitoring.  Surveil-
lance tests include measuring Tg levels while on and 
off thyroid hormone (or stimulated with rhTSH), neck 
ultrasounds, and 131I total body scans (TBSs). For pa-
tients with detectable Tg and negative TBSs, FDG-PET 
scanning is commonly employed. Which tests should 
be done and the time interval between testing must be 
tailored to the individual  recurrence risk of the pa-
tient.  
Therapeutic Options for Advanced DTC 
 Patients with progressive DTCs that are not re-
sponsive  to  standard  treatment  require  additional 
therapy. Treatment should focus both on gaining local 
disease control in the neck as well as the management 
of systemic disease. Neck dissection should be con-
sidered even in the setting of metastatic disease espe-
cially if cancer threatens vital neck structures. The role 
of  external  beam  radiation  (EBRT)  to  control  neck 
disease in DTC has not been established; it is unclear 
whether  it  improves  survival.  Still,  EBRT  may  help 
provide  local  control.  Cytotoxic  chemotherapy  has 
been used to treat systemic disease but the efficacy is 
poor. Doxorubicin is FDA-approved for treatment of 
thyroid  cancer,  but  response  rates  are  low  and 
short-lived.  Combination  chemotherapy  with  doxo-
rubicin and agents such as cisplatin have been associ-
ated  with  increased  toxicity  without  improved  re-
sponse or clear impact on survival.21  
 In  recent  years,  new  targeted  agents  for  the 
treatment of advanced thyroid cancer have emerged. 
The rationale for these agents is that they target and 
block  known  aberrancies  in  thyroid  carcinoma, 
namely constitutive activation of the MAPK and/or 
PI3 pathway and vascular endothelial growth factor 
receptors (VEGFRs) (Figure 1). Constitutive activation 
of the RET receptor via RET/PTC rearrangements and 
activating mutations of BRAF are commonly reported 
in PTCs whereas RAS mutations are common in FTC. 
VEGF, a stimulator of angiogenesis, likely contributes 
to tumor progression. Importantly, tumors with BRAF 
mutations  are  have  been  associated  with  increased 
risk of recurrence.22 
 To date, there have been several Phase II studies 
evaluating targeted agents in advanced thyroid cancer 
(Table  1).  Most  of  these  agents  are  tyrosine  kinase 
inhibitors (TKIs) that have activity against pathways 
that are implicated in DTC. Several agents have mul-
tiple  targets;  some  studies  include  all  subtypes  of 
thyroid cancer. 
Axitinib and motesanib diphosphate are two oral 
investigational agents with activity against VEGFRs. 
A Phase II study of axitinib in advanced thyroid can-
cer enrolled 60 patients (30 PTC, 15 FTC, 12 MTC, 2 
ATC, 1 other) who failed standard therapy.23 Docu-
mentation  of  progressive  disease  was  not  required. 
On an intention-to-treat analysis, 30% of patients (7 
PTC, 7 FTC, 3 MTC, 1 ATC) had a partial response 
and 38% of patients had stable disease greater than 16 
weeks.  A  Phase  II  study  of  motesanib  included  93 
patients with progressive DTC with evidence of pro-
gression.24 Of 92 patients available for evaluation, 14% 
had a partial response by RECIST and 35% had dura-
ble stable disease for greater than 24 weeks. Common 
adverse events with VEGFR inhibitors included hy-
pertension, fatigue and diarrhea.  
 Journal of Cancer 2011, 2 
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FIGURE 1. Schema of key pathways in the development and progression of thyroid cancer. 
 
 
TABLE 1. Targeted agents under clinical evaluation for the treatment of advanced thyroid cancer. 
Compound  Class  Thyroid cancers 
Axitinib  Tyrosine Kinase Inhibitor (TKI)  DTC, MTC, ATC 
Motesanib Diphosphate  TKI  DTC 
Pazopanib  TKI  DTC 
Sorafenib  TKI  DTC 
Sunitinib  TKI  DTC, MTC, ATC 
Thalidomide  Inhibitor of angiogenesis  DTC, MTC 
Lenalidomide  Inhibitor of angiogenesis  DTC 
 
 
Pazopanib is a TKI targeting several kinases in-
cluding VEGFR, platelet-derived growth factor, and 
c-KIT. A Phase II study recruited 39 patients with io-
dine-refractory  DTC  with  evidence  of  progression 
within  6  months  of  enrollment.25  Confirmed  partial 
responses were recorded in 49% of 37 evaluable pa-
tients, the highest response rate yet reported in pa-
tients  with  DTC.  The  likelihood  of  response  lasting 
longer than 1 year was calculated at 66%. Common 
adverse  events  included  fatigue,  skin  and  hair  hy-
popigmentation, diarrhea, and nausea.  
 Sorafenib  is  an  oral  TKI  with  activity  against 
multiple kinases including BRAF, VEGFR and RET. It 
is currently indicated for the treatment of advanced 
renal cell carcinoma and unresectable hepatocellular 
carcinoma. Sorafenib has shown cytostatic effects in 
thyroid tumor cells lines, both with and without the 
presence  of  BRAF  mutations.26,  27  Data from  several 
clinical studies of sorafenib for the treatment of ad-
vanced thyroid cancer have been reported. One trial 
evaluated sorafenib in 41 patients with PTC.28 A total 
of 6 patients (15%) had a partial response. Another 
56%  of  patients  had  stable  disease  longer  than  6 
months. A second study enrolled 55 patients (25 PTC, 
19  FTC/HCC,  4  MTC,  5  ATC)  with  metastatic,  io-
dine-refractory thyroid cancer.29 Median PFS was 84 
weeks.  Sixteen  patients  had  completed  BRAF  geno-
typing.  Interesting,  patients  with  PTC  tumors  har-
boring BRAFV600E mutations had significantly longer 
PFS (84+weeks) compared to patients with PTC/FTC Journal of Cancer 2011, 2 
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wild type BRAF (54 weeks). Preliminary data from a 
third Phase II study of sorafenib in advanced thyroid 
cancer  have  been  presented.30  Some  18  patients  (10 
MTC, 8 DTC) with progressive thyroid cancer were 
enrolled. Of 10 patients evaluable at 3 months, 9 had 
stable disease and 1 had a partial response.  
 Sunitinib is an oral TKI with multiple targets in-
cluding  PDGFR,  VEGFR,  Kit  and  RET.  Sunitinib  is 
currently  indicated  for  the  treatment  of  metastatic 
renal cell cancer and for imatinib-resistant gastroin-
testinal stromal tumors. Preliminary results of three 
Phase  II  studies  of  sunitinib  in  advanced  thyroid 
cancer have been presented. In one study, 43 subjects 
(37 DTC, 6 MTC) with progressive disease within the 
previous 6 months who failed standard therapy were 
enrolled.31 Of 31 patients with DTC who completed 2 
cycles, 13% had a partial response and 68% had stable 
disease. In a second trial, 17 patients with advanced 
thyroid cancer (8 PTC, 4 MTC, 1 ATC, 4 other) were 
enrolled. Of 15 patients evaluable at 3 months, 1 had a 
partial response and 12 patients had stable disease.32 
A third trial of sunitinib in advanced thyroid cancer 
enrolled 18 patients (15 DTC, 3 MTC).33 Although 44% 
of patients had a radiographic response on FDG-PET 
scanning,  response  rates  by  RECIST  have  not  been 
reported.  
 Promising data on the activity of sorafenib and 
sunitinib in advanced thyroid cancer have led to the 
inclusion of both drugs on the NCCN Drug and Bio-
logic  Compendium™.  The  NCCN  Clinical  Practice 
Guidelines  in  Oncology™  for  Thyroid  Carcinoma 
recommends the use of sorafenib or sunitinib for sys-
temic  metastatic  disease  when  a  clinical  trial  is  not 
available or appropriate.34 
 Thalidomide is different than the novel agents 
described above in that it is not a TKI. Although tha-
lidomide was developed as a sedative in the 1950s, it 
was found to be teratogenic. However, thalidomide 
was observed to have antiangiogenic properties, alt-
hough its mechanism of action is uncertain. A Phase II 
study of thalidomide enrolled 36 patients (13 PTC, 4 
FTC,  8  HCC,  4  insular,  7  MTC)  with  radioio-
dine-unresponsive  progressive  disease.35  Of  28  pa-
tients available for evaluation, 5 had partial responses 
and 9 had stable disease. Serious adverse events in-
cluded infection, pericardial effusion, and pulmonary 
embolus.  More  recently,  preliminary  results  from  a 
Phase II study with lenalidomide, a derivative of tha-
lidomide with less toxicity, have been reported.36 A 
total of 25 patients with iodine-refractory DTC were 
initiated on 25 mg of oral lenalidomide daily. Of 18 
evaluable  patients,  22%  had  a  partial  response  and 
44% had stable disease. 
 Targeted therapy presents new therapeutic op-
tions  for  patients  with  advanced  thyroid  cancer. 
However, criteria for ideal candidates for these new 
therapies  continue  to  evolve.  While  early  trials  in-
cluded patients  with measurable but stable disease, 
most  recent  studies  have  focused  on  patients  with 
progressive  disease  as  these  patients  suffer  higher 
morbidity and mortality from their cancers and the 
toxicities of targeted agents are perhaps better justi-
fied. Importantly, randomized-controlled studies are 
now  underway  to  assess  whether  targeted  agents 
improve survival.  
Pharmacoeconomics 
The cost associated with the increasing incidence 
of thyroid cancer is not well-understood. A thorough 
investigation  of  the  literature  did  not  identify  pub-
lished  data  regarding  overall  costs  related  to 
non-metastatic thyroid cancer, long term management 
of low-risk thyroid cancer or repeat RAI for refractory 
disease.  Because  most  thyroid  cancer  is 
non-metastatic and the number of these cases contin-
ues to increase, the cost related to therapy will surely 
rise. There has been cost analysis on the use of rhTSH 
for remnant ablation compared to thyroid hormone 
withdrawal.37-39  A  recent  study  suggests  cost  effec-
tiveness of rhTSH in the US depends on variations in 
cost of rhTSH, rates of remnant ablation, productivity 
loss from time off work and quality of life.37  
 Health  care  costs  of  newly  metastatic  thyroid 
cancer have been investigated. A retrospective longi-
tudinal cohort study using a large (~14 million cov-
ered lives) US health-insurance claims database , an-
alyzed the costs of health related interventions in 183 
patients  with  newly  metastatic  thyroid  cancer  be-
tween 2003 and 2005.40 Inpatient care was the main 
driver of the total healthcare expenditure, and repre-
sented 43% of all costs. Radiation therapy was used in 
23%, 131I therapy in 19%, thyroid surgery in 13%, and 
chemotherapy  in  11%  of  patients.  The  costs  were 
substantial and totaled $60,196 per patient during the 
first year and $35,189 during the second year of fol-
low-up. This study did not consider newer targeted 
agents, which will likely increase costs as well. 
 Because the use of targeted agents in advanced 
thyroid cancer is recent, no economic analyses in this 
setting  have  been  performed.  However,  pharmaco-
economic studies of sorafenib and similar agents have 
been  published  in  renal  cell  carcinoma  (RCC)  and 
hepatocellular carcinoma.  The National Institute for 
Health and Clinical Excellence (NICE) in the UK, has 
issued its final appraisal on the cost-effectiveness of 
sorafenib  for  RCC  patients  in  who  failed  immuno-
therapy.41  With  a  value  of  £65,900  per  quali-
ty-adjusted life year (QALY) gained, NICE considered Journal of Cancer 2011, 2 
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sorafenib not to be cost-effective. Similarly, the NICE 
Committee  considered  that  the  incremental 
cost-effectiveness  ratio  (ICER)  of  sorafenib  as  se-
cond-line  treatment  for  RCC  patients  in  whom 
non-immunotherapy  first-line  treatment  has  failed, 
and who are unsuitable for immunotherapy, would 
also  not  be  a  cost-effective  use  of  the  UK  National 
Health Service resources.41  
 The appraisal of sorafenib in hepatocellular car-
cinoma  has  also  been  evaluated.  The  manufacturer 
(Bayer) submitted evidence to the NICE Committee in 
which sorafenib compared with best supportive care 
(BSC)  produced  a  base-case  ICER  of  £64,754  per 
QALY gained. The NICE Committee, however, issued 
a  preliminary  appraisal  document  with  an  ICER  of 
£76,067, and stated that sorafenib as a treatment for 
advanced  hepatocellular  carcinoma  in  patients  for 
whom surgical or locoregional therapies had failed or 
were not suitable, is not cost-effective.42 From the U.S. 
payer  perspective,  a  recent  economic  evaluation  of 
sorafenib  in  unresectable  hepatocellular  carcinoma 
versus BSC estimated that the ICER was $62,473 per 
QALY  gained.43  Of  note,  these  studies  were  per-
formed in malignancies in which the efficacy of so-
rafenib  has  been  demonstrated  in  random-
ized-controlled  studies.  Nevertheless,  these  evalua-
tions do illustrate the complex issue of cost and effec-
tiveness with new targeted agents. 
 The addition of targeted drugs has the potential 
to substantially alter the cost of treatment of advanced 
thyroid  cancer.  Thus,  as  resources  are  scarce,  phar-
macoeconomic  and  quality  of  life  analyses  of  these 
different drugs in the US setting will be mandatory. 
Conclusions 
The  cost  associated  with  the  management  of 
thyroid cancer is bound to increase in coming years. 
Part of this increase will likely be from costs incurred 
for the standard treatment of PTC, as this subtype of 
thyroid cancer has seen a large increase in diagnosis. 
Controlling  cost  while  still  providing  optimal  care 
will  require  better  risk  stratification  in  low-risk  pa-
tients. While certain factors such as increasing age or 
male  gender  increase  a  patient’s  chance  of  having 
progressive  disease,  current  diagnostic  tools  are  in-
adequate to accurately predict which patients will do 
well  with  minimal  therapy.  While  surgery  remains 
necessary for adequate staging, more judicious use of 
RAI may help control costs. In the future, newer tools, 
such as molecular genetics to detect more or less ag-
gressive cancers, may aid clinicians in recommending 
the most appropriate therapy. 
 Although patients with advanced thyroid cancer 
represent a minority of patients, they require contin-
ued evaluation and therapy which will also increase 
health  care  expenditures.  Although  many  of  these 
patients  receive  targeted  therapy  as  part  of  clinical 
trials, the availability of sorafenib and sunitinib pro-
vides  options  when  trials  are  not  available.  These 
agents do have significant toxicities and costs; there-
fore, identifying which patients with metastatic dis-
ease are likely to benefit novel therapies remains an 
important research question. At present, results from 
randomized studies are needed to investigate whether 
targeted  agents  improve  survival.  Whether  these 
agents  are  cost  effective  remains  an  unknown  but 
important question. 
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